Targeted therapies: Molecular selection for 'smart' study design in lung cancer.
Psyrri
Amanda
A
Burtness
Barbara
B
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077143:Docetaxel; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005819:Genetic Markers; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000235:genetics*; D010597:Pharmacogenetics; D010880:Piperidines / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use*; D043823:Taxoids / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D005819:Genetic Markers; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D043823:Taxoids; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride; D066246:ErbB Receptors; C452423:vandetanib